These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36754622)

  • 61. [The new approval procedure for clinical trials of medicinal products in the European Union-challenges for the pharmaceutical industry in Germany].
    Henn DK; Ruppert T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2023 Jan; 66(1):28-37. PubMed ID: 36449064
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 63. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 64. First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA Member States.
    Valenciano M; Ciancio B; Moren A;
    Euro Surveill; 2008 Oct; 13(43):. PubMed ID: 18947520
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Restrictions on import of drugs for personal use within the European single market.
    Mäkinen MM; Rautava PT; Forsström JJ
    Eur J Public Health; 2002 Dec; 12(4):244-8. PubMed ID: 12506498
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Regional Differences During the ICH Regulatory Consultation Process Between the EU, US, and Japan.
    Torqui A; Macau AM
    Ther Innov Regul Sci; 2018 Jul; 52(4):438-441. PubMed ID: 29714552
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The added value of a European Union tuberculosis reference laboratory network--analysis of the national reference laboratory activities.
    Drobniewski FA; Nikolayevskyy V; Hoffner S; Pogoryelova O; Manissero D; Ozin AJ
    Euro Surveill; 2008 Mar; 13(12):. PubMed ID: 18761994
    [TBL] [Abstract][Full Text] [Related]  

  • 69. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
    Martinac AI; Tomić S; Simicić M
    Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Causes of drug shortages in the legal pharmaceutical framework.
    De Weerdt E; Simoens S; Hombroeckx L; Casteels M; Huys I
    Regul Toxicol Pharmacol; 2015 Mar; 71(2):251-8. PubMed ID: 25591547
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges.
    Vella Bonanno P; Cassar V; Godman B
    Front Pharmacol; 2021; 12():666405. PubMed ID: 34867312
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Does EU and US paediatric legislation improve the authorization availability of medicines for children in other countries?
    Volodina A; Shah-Rohlfs R; Jahn A
    Br J Clin Pharmacol; 2023 Mar; 89(3):1056-1066. PubMed ID: 36189466
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Fighting falsified medicines with paperwork - a historic review of Danish legislation governing distribution of medicines.
    Borup R; Kaae S; Minssen T; Traulsen J
    J Pharm Policy Pract; 2016; 9():30. PubMed ID: 27713830
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Addressing the impact of economic sanctions on Iranian drug shortages in the joint comprehensive plan of action: promoting access to medicines and health diplomacy.
    Setayesh S; Mackey TK
    Global Health; 2016 Jun; 12(1):31. PubMed ID: 27267898
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [More transparency in clinical research: How are the new transparency regulations assessed from the perspective of the pharmaceutical industry?].
    Wachenhausen H; Peters J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2023 Jan; 66(1):60-67. PubMed ID: 36542105
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gap in publication of comparative information on new medicines.
    van Luijn JC; Stolk P; Gribnau FW; Leufkens HG
    Br J Clin Pharmacol; 2008 May; 65(5):716-22. PubMed ID: 18294324
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
    Tomasi PA; Egger GF; Pallidis C; Saint-Raymond A
    Paediatr Drugs; 2017 Dec; 19(6):505-513. PubMed ID: 28900869
    [TBL] [Abstract][Full Text] [Related]  

  • 78. EU alerting and reporting systems for potential chemical public health threats and hazards.
    Orford R; Crabbe H; Hague C; Schaper A; Duarte-Davidson R
    Environ Int; 2014 Nov; 72():15-25. PubMed ID: 25023642
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [European registration of veterinary drugs].
    Reijnders PJ
    Tijdschr Diergeneeskd; 1993 Apr; 118(8):271-4. PubMed ID: 8484182
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Good manufacturing practice: the role of local manufacturers and competent authorities.
    Tomić S; Filipović Sučić A; Ilić Martinac A
    Arh Hig Rada Toksikol; 2010 Dec; 61(4):425-36. PubMed ID: 21183434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.